Dr. Reddy’s Announces the Relocation of Their North America Headquarters and Establishment of a R&D Center in Princeton, NJ,

  Dr. Reddy’s Announces the Relocation of Their North America Headquarters and
  Establishment of a R&D Center in Princeton, NJ, USA

Business Wire

HYDERABAD, India -- April 9, 2013

Dr. Reddy’s Laboratories (NYSE: RDY) today announced plans to relocate their
North America Headquarters and establish a R&D Center inPrinceton, New
Jersey. Dr. Reddy’s, represented by Jones Lang LaSalle, has entered into two
lease agreements for a 75,500 square foot office facility and a 31,000 square
foot office/lab at 107 College Road East and 303 College Road East
respectively with National Business Parks.

Dr. Reddy’s anticipates relocation to the office facility at 107 College Road
East by the end of the summer of 2013 after the renovations to the facility
are completed. The new North America Headquarters will house the Generics,
Biologics, PSAI and Proprietary Product businesses as well as the corporate
support functions within North America. It is projected to employ 300+ people
as the US businesses within Dr. Reddy’s continue to expand in the coming
years.

The lab facility located at 303 College Road East will undergo a redesign to
accommodate Dr. Reddy’s product development and analytical laboratory
requirements. Approximately 20,000 square feet of space will be part of the
initial phase of redesign. The lab facility is also expected to be completed
by late summer to early fall of 2013 and will employ 35 scientists, chemists
and support personal.

Commenting on the move, GV Prasad, Chairman and CEO, Dr. Reddy’s said, “The
relocation will allow Dr. Reddy's to tap into local talent which will be
instrumental in our long term growth. This R&D center, along with centers in
Cambridge (UK) and Leiden (Netherlands) establishes our presence within some
of the leading innovation centers of the world.”

Disclaimer

This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars, differentiated formulations
and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management, anti-infective and pediatrics. Major
markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com

Contact:

Dr. Reddy’s Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, kedaru@drreddys.com, +91-40-66834297
Saunak Savla, saunaks@drreddys.com, +91-40-49002135
Milan Kalawadia (USA), mkalawadia@drreddys.com, +1 908-203-4931
or
Media:
S Rajan, rajans@drreddys.com, +91-40-49002445